The Percutaneous Transluminal Angioplasty (PTA) catheter is not labeled for use in the coronary or neuro-vasculature.
Thomas Trotter, president and CEO of AngioScore, said: “This latest 510(k) clearance to market for our AngioSculpt PTA catheter now enables us to address several of the largest and fastest growing segments of the peripheral artery disease market in the US, including the superficial femoral artery and stenoses involving hemodialysis of synthetic or native arteriovenous fistulae.”